27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
(Biotech Stocks Hitting 52-week Highs Nov. 3)
- Bio-Rad Laboratories, Inc. (NYSE:BIO)
- Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
- BioLife Solutions Inc (NASDAQ:BLFS)
- BioLineRx ADR Representing 15 Ord Shs (NASDAQ:BLRX)(reacted to positive readout for its stem cell therapy to treat cancer)
- Halozyme Therapeutics, Inc. (NASDAQ:HALO)(reacted to its quarterly results)
- Idera Pharmaceuticals Inc (NASDAQ:IDRA)
- Inspire Medical Systems Inc (NYSE:INSP) ( reported strong results for the third quarter)
- Immunovant Inc (NASDAQ:IMVT)
- Scholar Rock Holding Corp (NASDAQ:SRRK)
- Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)
- United Therapeutics Corporation (NASDAQ:UTHR)
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows Nov. 3)
- Abeona Therapeutics Inc (NASDAQ:ABEO)
- Aprea Therapeutics Inc (NASDAQ:APRE)
- Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
- Benitec Biopharma Inc (NASDAQ:BNTC)
- Esperion Therapeutics Inc (NASDAQ:ESPR) (reacted to its quarterly results)
- Happiness Biotech Group Ltd (NASDAQ:HAPP)
- Jaguar Health Inc (NASDAQ:JAGX)
- Liminal BioSciences Inc (NASDAQ:LMNL)
- Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV)
- Neovasc Inc (NASDAQ:NVCN)
- Opthea Spon (NASDAQ:OPT)
- Silence Therapeutics ADR (NASDAQ:SLN)
- Titan Pharmaceuticals, Inc (NASDAQ:TTNP)
Stocks In Focus
Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires
Bristol-Myers Squibb Co (NYSE:BMY) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire all outstanding shares of Myokardia Inc (NASDAQ:MYOK) expired.
This satisfies one of the conditions necessary for the consummation of the transaction, and the consummation is now contingent on the tender of a majority of the outstanding shares of MyoKardia's common stock, as well as other customary closing conditions.
The tender is scheduled to expire by Nov. 16 at 11:59 pm.
Soleno Presents Positive Body Composition Data From a Late-stage Prader-Willi Syndrome Study
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Soleno Therapeutics Inc (NASDAQ:SLNO) announced presentation of positive body composition data from its Phase 3 trial, evaluating once-daily diazoxide choline controlled-release tablets for patients with Prader-Willi Syndrome at the Obesity Society's ObesityWeek 2020 meeting.
The results showed significant reductions in fat mass after 13 weeks of double-blind treatment, a significant reduction in leptin and an increase in adiponectin, a cardioprotective hormone.
"The data presented to date show that DCCR has the potential to manage both behavioral and co-morbid metabolic components of PWS," said Parisa Salehi, a clinician at Seattle Children's Hospital.
Earnings
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) reported third-quarter revenues of $155.14 million, higher than $102.14 million last year. The earnings per share climbed from 54 cents to 74 cents, notably higher than the 30-cent per share consensus estimate. The company raised its guidance for full-year 2020.
The stock rallied 20.88% to $21.94 in after-hours trading.
Five Prime Therapeutics Inc's (NASDAQ:FPRX) third-quarter revenues fell from $2.984 million to $2.048 million. The loss per share, though narrowing from $1.03 to 74 cents, was wider than the consensus loss estimate of 60 cents per share.
The stock was down 10.79% to $4.30 in after-hours trading.
On The Radar
Clinical Readouts
vTv Therapeutics Inc (NASDAQ:VTVT) will make an oral presentation at the CTAD, providing a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer's disease in adult patients who also have type 2 diabetes.
Earnings
Haemonetics Corporation (NYSE:HAE) (before the market open)
Aquestive Therapeutics Inc (NASDAQ:AQST) (after the close)
Anika Therapeutics Inc (NASDAQ:ANIK) (after the close)
Axonics Modulation Technologies Inc (NASDAQ:AXNX) (after the close)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (after the close)
T2 Biosystems Inc (NASDAQ:TTOO) (after the close)
OraSure Technologies, Inc. (NASDAQ:OSUR) (after the close)
Hologic, Inc. (NASDAQ:HOLX) (after the close)
Otonomy Inc (NASDAQ:OTIC) (after the close)
SurModics, Inc. (NASDAQ:SRDX) (after the close)
Sangamo Therapeutics Inc (NASDAQ:SGMO) (after the close)
PRA Health Sciences Inc (NASDAQ:PRAH) (after the close)
Cytosorbents Corp (NASDAQ:CTSO) (after the close)
Lineage Cell Therapeutics Inc (NYSE:LCTX) (after the close)
Insulet Corporation (NASDAQ:PODD) (after the close)
Cytokinetics, Inc. (NASDAQ:CYTK) (after the close)
MannKind Corporation (NASDAQ:MNKD) (after the close)
Flexion Therapeutics Inc (NASDAQ:FLXN) (after the close)
DiaMedica Therapeutics Inc (NASDAQ:DMAC) (after the close)
Orthopediatrics Corp (NASDAQ:KIDS))
Ionis Pharmaceuticals Inc (NASDAQ:IONS)
G1 Therapeutics Inc (NASDAQ:GTHX)
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
Other Events
The FDA is due to release the briefing document related to Biogen Inc's (NASDAQ:BIIB) BLA for aducanumab for the treatment of Alzheimer's disease.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.